On October 30, 2019, Aimed Alliance summitted a comment to the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee. In the comment, Aimed Alliance recommended that the Committee approve the pending supplemental new drug application for Vascepa to reduce the risk of cardiovascular events as an adjunct to statin therapy in adult patients with elevated triglyceride levels. We made this recommendation because the medication was shown to improve health outcomes and fill an unmet need for patients with or at risk for cardiovascular disease. Read our comment here.
Last Updated on May 18, 2020 by Aimed Alliance
